Price (90d)
$322.10Signal Score (90d)
70Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.31B | $-208.16M | $-1.52 |
| 2024 | $1.70B | $-190.43M | $-1.53 |
| 2023 | $1.08B | $-434.80M | $-3.78 |
| 2022 | $820.22M | $-547.80M | $-5.57 |
| 2021 | $625.49M | $-471.72M | $-5.21 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.23 per share
Typical surprise -3.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.47 vs $-0.49beat
- Thu, May 7$-0.56 vs $-0.54miss
- Thu, Feb 26$0.35 vs $-0.51beat
- Thu, Nov 6$-0.64 vs $-0.39miss
- Thu, Aug 7$-0.74 vs $-0.62miss
- Thu, May 8$-0.50 vs $-0.64beat
Estimates and results for NTRA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
NTRAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (5)
- Newsseekingalpha.com·2d ago·Positive
Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - News (RSS)investing·3d ago·Neutral
Natera partners with Kupando for phase 1 cancer trial in Germany
View source ↗ - Newsbusinesswire.com·3d ago·Negative
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics. Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando's clinical trial of its lead immunotherapy ca
View source ↗ - Newsfool.com·6d ago·Positive
Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead. Druckenmiller only owns one "Magnificent Seven" stock.
View source ↗ - Newsforbes.com·7d ago·Negative
Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status 40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company's lowest closing price this year occurred in late March, when shares fell to $182.65.
View source ↗